Characterisation of a DNA repair deficiency (DRD) biomarker phenotype in metastatic urothelial carcinoma (mUC) within the ATLANTIS clinical trial platform

A subset of mUC exhibits a DRD phenotype predicting benefit from platinum based chemotherapy (PBC). We previously reported switch maintenance therapy with the PARP inhibitor rucaparib, following PBC, in patients with mUC harbouring a DRD biomarker. Rucaparib extended progression free survival (Crabb et al, J Clin Oncol 40, 2022 (suppl 6; abstr 436)). We undertook an exploratory analysis of the phenotypic and genomic characteristics of the DRD biomarker allocated cohort, involving all patients from the ATLANTIS clinical trial where next generation sequencing (NGS) was possible.